We examined developmental programming studies that reported sex-specific effects 29 published between 2012 and 2014, and examined whether the authors reported a 30 statistical approach to explicitly test whether the effect of treatment differed between the 31 sexes, e.g., a sex by treatment interaction term. Less than half of the studies that reported 32 sex-specific effects described explicitly testing whether effects were indeed sex-specific; 33 in most cases, an effect was considered "sex-specific" if it was significant in one sex but 34 not the other. This is not a robust approach, since significance in one sex and lack of 35 significance in the other sex does not imply a significant difference between the sexes. 36
INTRODUCTION 45
Recently, there has been increasing interest in sex-specific effects of 46 developmental programming 1, 2 . Literature searches on PubMed and Web of Science 47 from 2000 to 2014 show that there has been a substantial increase in studies examining 48 sex-specific effects of developmental programming -searches for the terms "sex-specific 49 or sex-dependent" and "fetal or development" and "programming" yielded only 14 50 studies published in 2000 and 84 studies published in 2014. Differential susceptibility to 51 developmental programming between the sexes has been demonstrated widely in animal 52 models 2 . Moreover, funding agencies such as National Institutes of Health (NIH) and 53
Canadian Institutes for Health Research (CIHR) are increasingly encouraging the 54 incorporation of gender and sex into research designs where appropriate. 55
In assessing whether effects are sex-specific, it is necessary to explicitly test 56 whether an effect differs between the sexes; performing analyses separately for each sex 57 is not sufficient. For example, if the effect of treatment is significantly different from 58 zero in males, but not in females, it does not necessarily follow that the effect size in 59 males is significantly different from the effect size in females. A non-significant effect in 60 females is not evidence that the effect size in females is actually zero. Conversely, if the 61 effect of treatment is significant and in the same direction in both sexes, it does not 62 necessarily follow that the magnitude of the effect of treatment is equal in both sexes . 63
We argue that, in order to report an effect as "sex-specific" or "sex-dependent", it is 64 necessary to perform an explicit test of the difference in effect size between the sexes, 65 e.g., using a sex by treatment interaction term in the statistical model. We examined the 66 reporting of statistical models in experiments that reported sex-specific effects of 67 while the others analyzed the sexes separately using ANOVAs followed by Bonferroni or 90
Dunnet's post-hoc tests. 91
92

DISCUSSION 93
Only a third of studies reporting sex differences in developmental programming 94 effects included a sex by treatment interaction term in their statistical models. Instead the 95 sexes were analyzed separately, and significant effects detected in only one sex were 96 described as sex-specific. However, this is not a robust approach, and studies in 97 developmental programming should include explicit statistical tests for sex-specific 98 effects, e.g., by including interaction terms between sex and treatment. 99 While small sample sizes may limit the statistical power to detect interactions, this 100
is not a justification for excluding explicit statistical tests for sex-specific effects. Where 101 the sex by treatment interaction term is not significant, an alternative approach would be 102 to report confidence intervals for the magnitude of effect in each sex. While confidence 103 intervals would overlap between the sexes if the interaction was not significant, this 104 approach would illustrate the potential magnitude of differences between the sexes. 105
Another alternative approach would be the use of Bayesian analysis. Traditional 106 null hypothesis significant testing (NHST) uses P-values, which describe the probability 107 of observing the test statistic or one more extreme if the null hypothesis is true (e.g., there 108 is no effect of treatment). In contrast, Bayesian analysis quantify degree of belief or 109 uncertainty in a parameter or hypothesis using probability distributions 3 . Thus, while 110 NHST calculates describe the probability of observing the test statistic or one more 111 extreme, given some null hypothesis, Bayesian approaches calculate the probability of 112 6 some hypothesis or parameter value, given the data 4 . Therefore, Bayesian approaches 113 actually allow more intuitive statements to be made than does NHST. While Bayesian 114 approaches provide the opportunity to incorporate prior knowledge into analyses, it is 115 possible to use prior distributions that are uninformative, i.e., that have little impact on 116 the results 3 . Bayesian analysis begins with a prior probability distribution (e.g., for 117 parameter values) and uses the prior and sample data to produce a posterior distribution, 118 from which one can determine the probability of some parameter value, given the data and an open-source package available for R 6 . This approach focuses not on whether or 124 not the difference in effect size between males and females is statistically significant (i.e., 125 different from zero), but on the level of confidence that this difference is sufficiently 126 large to be biologically interesting, which is arguably a more important issue. Our 127 example illustrates the flexibility of Bayesian analysis, which allows one to calculate the 128 probability of a customized parameter value or hypothesis. Furthermore, while Bayesian 129 approaches may currently be unfamiliar to many biologists and clinicians, the analyses 130 that we have described are very easy to implement. This approach provides probabilities 131 that are straightforward to interpret, but does not provide a clear-cut, "significant or not" 132 answer in the way that a P-value might. However, NHST does not necessarily provide 133 less ambiguous results, e.g., a non-significant P-value does not provide evidence that an 134 effect does not exist, and conversely a significant P-value does not necessarily indicate7 that an effect is biologically important. Furthermore, because NHST reduces the results to 136 a dichotomy (significant or not), with small sample sizes one is more likely accept the 137 null hypothesis even if it is false, i.e., commit a type II error. With small sample sizes, 138 there will be more uncertainty in Bayesian estimates 7 , but there will not be a greater 139 chance of error. Therefore, even if sample size limits the statistical power to detect a sex 140 by treatment interaction term, Bayesian approaches allow researchers in developmental 141 programming to assess the probability of sex-specific effects. To illustrate a Bayesian approach, we have simulated a data set where a trait has 167 been measured in male and female individuals subjected to one of two treatments (Table  168 A1). When analyzing the sexes separately using a one-way ANOVA, there is a 169 significant effect of treatment on the trait in males (F 1,18 = 5.19; P = 0.04), but not in 170 females (F 1,18 = 0.03; P = 0.86). However, when analyzing the sexes together using a 171 two-way ANOVA and including a sex by treatment interaction term, the interaction is 172 marginally non-significant (F 1,36 = 3.46; P = 0.07). This is a situation in which many 173 authors would be inclined to report sex-specific effects, and yet we have argued that sex-174 specific effects should not be reported unless there is a significant sex by treatment 175 interaction term. A Bayesian analysis provides an alternative way to express the level of 176 confidence that effect size differs between males and females. 177
Before considering a Bayesian approach, it is necessary to consider what is tested 178 by including a sex by treatment interaction term in a model, i.e., whether the effect of 179 treatment differs between the sexes. If there are only two treatments, the sex by treatment 180 interaction can be quantified by a single number: the difference in effect size between 181 males and females, and the P-value for the interaction tests whether this number is 182 significantly different from zero. In our example, the effect size in males is (11.41 -183 10.13) = 1.28, whereas it is (10.16 -10.25) = -0.09 in females. Thus, the difference in 184 effect sizes is -0.09 -1.28 = -1.37 (note that this value could also be calculated as 1.37, 185 depending on which means are subtracted from which). While such estimates of the 186 magnitude of an interaction are often not reported, it is useful to consider this estimate 187 9 and whether a difference in effect size is biologically important, rather than simply 188 whether or not a difference is statistically significant from zero. (Table A2) . In other words, the sex by treatment 204 interaction is less than -0.86 in 75% of posterior samples. Thus, one could report that 205 there is a probability of 0.75 that the difference in effect size between males and females 206 is 0.86 or greater. If 0.86 was considered a biologically important difference, one could 207 conclude that there was a substantial probability (0.75) that the difference in effect 208 between males and females was biologically important. Note that the Bayesian approach 209 allows a more intuitive statement than that one would obtain from a traditional 210 confidence interval (e.g., "were we to repeat the experiment many times, the 95% 211 confidence interval would include the true value in 95% of repetitions"). 212
What if 0.86 was not considered a biologically important difference? One could 213 alternatively identify a different value for the sex by treatment interaction, and determine 214 its probability. This can be achieved quite easily using the distribution of the sex by 215 treatment interaction among posterior samples (which can be obtained using the 216
OUTPOST option in the BAYES statement in SAS, or the POSTERIOR function in 217 BayesFactor). For instance, if a difference in effect size of 1.2 would be considered 218 biologically important, one can determine where 1.2 occurs among the set of posterior 219 samples. In this example, among 10000 posterior samples, the 5836th lowest value is -220 1.20054 and the 5837th lowest value is 1.19970 (values will vary slightly from run to run 221 because the algorithm used by the analysis involves random simulation). Thus, one could 222 conclude that "there is a probability of 0.58 (5836/10000) that the effect size in males is 223 at least 1.2 units greater than that in females" (Table A2 ). Such a statement might not 224 provide very convincing support for the existence of a sex-specific effect. However, this 225 statement has incorporated consideration of what is or is not a biologically important 226 difference, in contrast to the observation that the effect is significant in one sex, but not in 227 the other. The selection of a "biologically important" effect size could be achieved 228 objectively, e.g., by using an effect size observed in a seminal paper in the field, or an 229 effect that would be considered clinically important in humans. 230
Discussing the difference in effect size in absolute terms will not be very intuitive 231 in many cases. There might be a variety of other thresholds to determine whether the 232 difference in effect size between males and females is biologically important. For 233 11 instance, it might be meaningful to express the difference in effect size as a percentage, 234 e.g., what is the probability that the difference in effect size between males and females is 235 at least 10% of the value in control males? This is possible using the posterior samples 236 from a Bayesian analysis by (1) calculating the difference in effect size between males 237 and females for each posterior sample, (2) calculating the mean value for control males in 238 each posterior sample, (3) assessing whether the difference in effect size is greater than 239 10% of the mean of control males in each posterior sample, and (4) counting the 240 proportion of posterior samples for which this condition is true, i.e., the posterior 241 probability that the difference in effect size between males and females is at least 10% of 242 the mean value in control males, which in this example is 0.62 (Table A2) . Again, this is 243 not convincing evidence of a sex-specific effect, but unlike traditional NHST, this 244 approach has assessed the evidence of a biologically important sex-specific effect. Thus, 245 this approach provides a more meaningful interpretation of the data than the traditional 246 approach described at the beginning of this example, i.e., one way ANOVAs performed 247 separately for each sex, without a sex by treatment interaction term. 
